109 related articles for article (PubMed ID: 21947831)
1. Relapsed diffuse large B-cell lymphoma: clinical utility of cell of origin.
Vose JM
J Clin Oncol; 2011 Nov; 29(31):4065-6. PubMed ID: 21947831
[No Abstract] [Full Text] [Related]
2. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
3. Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma.
Rigacci L; Puccini B; Iovino L; Martelli M; Finolezzi E; DI Lollo S; Doria M; Bosi A
J Chemother; 2011 Aug; 23(4):227-31. PubMed ID: 21803701
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characterization of 61 cases of diffuse large B-cell lymphoma with different prognosis].
Wang Q; Wei XD; Yin QS
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):136-7. PubMed ID: 22780933
[No Abstract] [Full Text] [Related]
5. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
[TBL] [Abstract][Full Text] [Related]
6. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
Zinzani PL; Pellegrini C; Argnani L; Broccoli A
Haematologica; 2016 Sep; 101(9):e385-6. PubMed ID: 27247321
[No Abstract] [Full Text] [Related]
7. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
8. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
9. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
10. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma.
Jost LM; Stahel RA;
Ann Oncol; 2005; 16 Suppl 1():i60-1. PubMed ID: 15888758
[No Abstract] [Full Text] [Related]
11. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
[TBL] [Abstract][Full Text] [Related]
12. [Long-term results of rituximab-based salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma].
Wang XX; Huang HQ; Xia ZJ; Lin XB; Cai QQ; Gao Y; Lin ZX; Lin TY; Jiang WQ
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Apr; 30(4):867-70. PubMed ID: 20423868
[TBL] [Abstract][Full Text] [Related]
13. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.
Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y
Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544
[TBL] [Abstract][Full Text] [Related]
14. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous diffuse large B-cell lymphoma with cranial vault and dura mater involvement.
Mascolo M; Piccolo V; Iannuzzo G; Di Lorenzo P; De Rosa G; Staibano S
J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):186-7. PubMed ID: 25174371
[No Abstract] [Full Text] [Related]
16. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
17. Intravascular large B cell lymphoma with haemophagocytic syndrome: a double lethal masquerade.
Adler NR; Sia CS; Polchleb C; Jane S; Aung AK
Intern Med J; 2015 Dec; 45(12):1310-2. PubMed ID: 26648194
[No Abstract] [Full Text] [Related]
18. Neural cell adhesion molecule (CD56)-positive B cell lymphoma of the urinary bladder.
Kawasaki T; Suzuki M; Sato A; Yashima-Abo A; Satoh T; Kato R; Kato Y; Obara W; Shimoyama T; Ishida Y; Sugai T
J Clin Pathol; 2016 Jan; 69(1):89-92. PubMed ID: 26391771
[No Abstract] [Full Text] [Related]
19. Primary diffuse large B-cell lymphoma of the palpebral conjunctiva.
Kim NJ; Khwarg SI
Can J Ophthalmol; 2007 Aug; 42(4):630-1. PubMed ID: 17641717
[No Abstract] [Full Text] [Related]
20. Loss of CD20 expression in relapsed diffuse large b-cell lymphoma: Clinical significance of an uncommon pathological finding.
Mitra S; Mukherjee S; Bhattacharyya M; Chakraborty H
Indian J Pathol Microbiol; 2016; 59(2):263-5. PubMed ID: 27166069
[No Abstract] [Full Text] [Related]
[Next] [New Search]
